Market Overview

Wedbush Lowers Cadence PT to $10 from $15


In a research note published today, Wedbush lowered its price target on Cadence Pharmaceuticals (Nasdaq: CADX) to $10 from $15, but reiterated an outperform rating on the stock. The research firm said equity dilution and a longer time frame to peak sales were catalysts for the trimmed price target.

“Our fair value was reduced by $3 due to the additional 21.8MM shares and by $2 due to pushing out our peak sales by one year. Our fair value is calculated based on sum-of-parts for each drug/indication combination using a 30% annual discount from our peak annual sales projections and 1-10x multiple depending on stage of development to reflect risk,” Wedbush said in a note.

California-based Cadence is a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.

Posted-In: Analyst Color News Price Target Reiteration FDA Intraday Update Markets Analyst Ratings


Related Articles (CADX)

View Comments and Join the Discussion!

Latest Ratings

ITWMorgan StanleyMaintains136.0
CCKMorgan StanleyMaintains72.0
BLKMorgan StanleyMaintains554.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Sterne Agee Adjusts EPS Estimate on Dick's Sporting Goods

International Council of Shopping Centers States the Obvious: People are Hunting for Bargains